Fumarate hydratase in cancer: A multifaceted tumour suppressor.


Journal

Seminars in cell & developmental biology
ISSN: 1096-3634
Titre abrégé: Semin Cell Dev Biol
Pays: England
ID NLM: 9607332

Informations de publication

Date de publication:
02 2020
Historique:
received: 12 03 2019
revised: 03 05 2019
accepted: 06 05 2019
pubmed: 16 5 2019
medline: 23 12 2020
entrez: 16 5 2019
Statut: ppublish

Résumé

Cancer is now considered a multifactorial disorder with different aetiologies and outcomes. Yet, all cancers share some common molecular features. Among these, the reprogramming of cellular metabolism has emerged as a key player in tumour initiation and progression. The finding that metabolic enzymes such as fumarate hydratase (FH), succinate dehydrogenase (SDH) and isocitrate dehydrogenase (IDH), when mutated, cause cancer suggested that metabolic dysregulation is not only a consequence of oncogenic transformation but that it can act as cancer driver. However, the mechanisms underpinning the link between metabolic dysregulation and cancer remain only partially understood. In this review we discuss the role of FH loss in tumorigenesis, focusing on the role of fumarate as a key activator of a variety of oncogenic cascades. We also discuss how these alterations are integrated and converge towards common biological processes. This review highlights the complexity of the signals elicited by FH loss, describes that fumarate can act as a bona fide oncogenic event, and provides a compelling hypothesis of the stepwise neoplastic progression after FH loss.

Identifiants

pubmed: 31085323
pii: S1084-9521(18)30202-7
doi: 10.1016/j.semcdb.2019.05.002
pmc: PMC6974395
mid: EMS82869
pii:
doi:

Substances chimiques

Fumarate Hydratase EC 4.2.1.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

15-25

Subventions

Organisme : Medical Research Council
ID : MC_UU_12022/6
Pays : United Kingdom

Informations de copyright

Copyright © 2019. Published by Elsevier Ltd.

Références

Cell Biochem Biophys. 2014 Apr;68(3):475-8
pubmed: 24068518
Nat Rev Cancer. 2018 Feb;18(2):128-134
pubmed: 29326430
Exp Mol Med. 2016 Jul 15;48(7):e245
pubmed: 27416781
Cell Metab. 2019 Feb 5;29(2):399-416.e10
pubmed: 30449682
Int J Cancer. 2012 Apr 15;130(8):1715-25
pubmed: 22025288
J Inherit Metab Dis. 2011 Jun;34(3):671-6
pubmed: 21445611
J Exp Med. 1915 Dec 1;22(6):766-79
pubmed: 19867957
Cell Rep. 2015 Dec 1;13(9):1895-908
pubmed: 26655904
Front Oncol. 2017 Nov 27;7:286
pubmed: 29230384
J Clin Endocrinol Metab. 2014 Oct;99(10):E2046-50
pubmed: 25004247
Int J Cancer. 2012 Jun 1;130(11):2599-606
pubmed: 21796619
Cell Rep. 2013 Mar 28;3(3):689-700
pubmed: 23499446
J Pathol. 2011 Sep;225(1):4-11
pubmed: 21630274
Cell Metab. 2014 Dec 2;20(6):939-52
pubmed: 25448702
Cancer Cell. 2018 Jul 9;34(1):21-43
pubmed: 29731393
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
N Engl J Med. 2016 Jan 14;374(2):135-45
pubmed: 26536169
Nature. 2011 Nov 20;481(7381):380-4
pubmed: 22101433
BMC Genomics. 2014 Feb 25;15:158
pubmed: 24568598
Cell Biosci. 2017 Nov 13;7:62
pubmed: 29158891
Cancer Cell. 2015 Feb 9;27(2):257-70
pubmed: 25670081
Annu Rev Biochem. 2018 Jun 20;87:585-620
pubmed: 29494239
Int J Nephrol Renovasc Dis. 2014 Jun 20;7:253-60
pubmed: 25018647
Nucleic Acids Res. 2017 Nov 2;45(19):11356-11370
pubmed: 28977517
Clin Chim Acta. 1983 Aug 31;132(3):301-8
pubmed: 6616883
Cancer Res. 2018 Dec 1;78(23):6539-6548
pubmed: 30297534
Elife. 2016 Feb 22;5:null
pubmed: 26901439
Biomol Concepts. 2014 Jun;5(3):209-24
pubmed: 25372754
Structure. 2000 Feb 15;8(2):163-74
pubmed: 10673438
Cancer Cell. 2011 Sep 13;20(3):315-27
pubmed: 21907923
N Engl J Med. 2015 Dec 10;373(24):2336-2346
pubmed: 26580448
Nat Commun. 2016 Oct 10;7:13041
pubmed: 27721378
Biol Reprod. 2009 Oct;81(4):749-58
pubmed: 19553600
Pharmacol Res. 2016 Mar;105:146-51
pubmed: 26816087
Cancers (Basel). 2014 Feb 26;6(1):436-58
pubmed: 24577242
Cancer Cell. 2011 Oct 18;20(4):524-37
pubmed: 22014577
Cancer Metab. 2013 Mar 21;1(1):12
pubmed: 24280230
Science. 2007 Nov 30;318(5855):1469-72
pubmed: 17991826
Acta Pharm Sin B. 2015 Sep;5(5):378-89
pubmed: 26579469
Cell Rep. 2018 Apr 3;23(1):313-326.e5
pubmed: 29617669
FEBS J. 2011 Nov;278(22):4230-42
pubmed: 21929734
J Biol Chem. 2001 Dec 7;276(49):46111-7
pubmed: 11585823
Cancer Res. 2016 Oct 1;76(19):5743-5755
pubmed: 27302170
Int J Obes (Lond). 2008 Sep;32 Suppl 4:S36-41
pubmed: 18719597
Hum Mol Genet. 2014 May 1;23(9):2440-6
pubmed: 24334767
Oncogene. 2009 Apr 9;28(14):1653-68
pubmed: 19234488
Can Urol Assoc J. 2015 Mar-Apr;9(3-4):E243-6
pubmed: 26085897
Cell Rep. 2017 Sep 26;20(13):3135-3148
pubmed: 28954230
Genes Dev. 2012 Jun 15;26(12):1326-38
pubmed: 22677546
Biochim Biophys Acta Bioenerg. 2017 Aug;1858(8):723-731
pubmed: 27956047
Biochim Biophys Acta. 2012 Sep;1823(9):1468-83
pubmed: 22610083
Metab Eng. 2018 Jan;45:149-157
pubmed: 29191787
J Mol Med (Berl). 2011 Mar;89(3):213-20
pubmed: 21301796
Nature. 2016 Aug 31;537(7621):544-547
pubmed: 27580029
Mol Cancer Ther. 2009 Mar;8(3):626-35
pubmed: 19276158
Cell Metab. 2006 Mar;3(3):187-97
pubmed: 16517406
J Inherit Metab Dis. 2010 Aug;33(4):411-9
pubmed: 20549362
J Pathol. 2005 Jan;205(1):41-9
pubmed: 15586379
Cell Rep. 2013 May 30;3(5):1440-8
pubmed: 23643539
Anal Biochem. 2018 Jul 1;552:50-59
pubmed: 28711444
Urol Int. 2013;90(2):233-9
pubmed: 23295344
PLoS Biol. 2010 Mar 09;8(3):e1000328
pubmed: 20231875
J Clin Invest. 2003 Mar;111(6):779-83
pubmed: 12639980
Traffic. 2016 Jul;17(7):720-32
pubmed: 27037871
Cancer Cell. 2014 Dec 8;26(6):840-850
pubmed: 25490448
Free Radic Biol Med. 2015 Nov;88(Pt B):101-107
pubmed: 26057936
Genes Dev. 2016 Apr 1;30(7):733-50
pubmed: 27036965
Cell Res. 2014 Dec;24(12):1403-19
pubmed: 25412662
Mol Cell Biol. 2017 May 16;37(11):
pubmed: 28289076
Nat Cell Biol. 2014 Jun;16(6):488-94
pubmed: 24875735
Cell Rep. 2018 Jul 31;24(5):1093-1104.e6
pubmed: 30067967
Oncol Rep. 2015 Dec;34(6):2821-6
pubmed: 26398719
Cancer Cell. 2005 Aug;8(2):143-53
pubmed: 16098467
Nature. 2011 Nov 20;481(7381):385-8
pubmed: 22101431
Mol Cell. 2015 Nov 19;60(4):547-60
pubmed: 26590714
Adv Cancer Res. 1998;72:141-96
pubmed: 9338076
PLoS One. 2013 Aug 15;8(8):e72179
pubmed: 23967283
Mol Cell. 2013 Jul 25;51(2):236-48
pubmed: 23747014
Interface Focus. 2017 Apr 6;7(2):20160100
pubmed: 28382199
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Nat Genet. 2002 Apr;30(4):406-10
pubmed: 11865300
Nat Commun. 2015 Jan 23;6:6001
pubmed: 25613188
Elife. 2017 Jan 18;6:
pubmed: 28099114
Cancer Cell. 2011 Oct 18;20(4):511-23
pubmed: 22014576
Nat Cell Biol. 2015 Sep;17(9):1158-68
pubmed: 26237645
Nat Chem Biol. 2019 Apr;15(4):391-400
pubmed: 30718813
Cell Metab. 2006 Mar;3(3):177-85
pubmed: 16517405
Arch Biochem Biophys. 2006 Jun 1;450(1):1-8
pubmed: 16624247
Nature. 2011 Aug 17;477(7363):225-8
pubmed: 21849978
Free Radic Biol Med. 2016 Nov;100:175-181
pubmed: 27117029
J Biol Chem. 2007 Feb 2;282(5):3293-301
pubmed: 17135241
Cell Rep. 2017 Oct 24;21(4):1036-1047
pubmed: 29069586
Cell Death Dis. 2018 Sep 6;9(9):913
pubmed: 30190474
Fam Cancer. 2014 Dec;13(4):637-44
pubmed: 25012257
Nat Biotechnol. 2013 Jun;31(6):522-9
pubmed: 23604282
J Med Res. 1913 Dec;29(2):217-32
pubmed: 19972139
Diabetes. 2008 Jan;57(1):41-9
pubmed: 17934141
JIMD Rep. 2018;40:77-83
pubmed: 29052812
Ann N Y Acad Sci. 2008 Apr;1126:272-5
pubmed: 18448829
Nat Genet. 2018 Aug;50(8):1086-1092
pubmed: 30013182
Science. 1956 Feb 24;123(3191):309-14
pubmed: 13298683
Hum Mol Genet. 2010 Oct 1;19(19):3844-51
pubmed: 20660115

Auteurs

Christina Schmidt (C)

Medical Research Council Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Box 197, Cambridge Biomedical Campus, Cambridge CB2 0XZ, United Kingdom.

Marco Sciacovelli (M)

Medical Research Council Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Box 197, Cambridge Biomedical Campus, Cambridge CB2 0XZ, United Kingdom. Electronic address: ms2122@mrc-cu.cam.ac.uk.

Christian Frezza (C)

Medical Research Council Cancer Unit, University of Cambridge, Hutchison/MRC Research Centre, Box 197, Cambridge Biomedical Campus, Cambridge CB2 0XZ, United Kingdom. Electronic address: cf366@mrc-cu.cam.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH